Comprehensive pharmacokinetics of urinary human follicle stimulating hormone in healthy female volunteers

The study determined the pharmacokinetics of urinary human follicle stimulating hormone (u-hFSH) in 12 down-regulated healthy female volunteers. Following pituitary desensitization, baseline FSH serum levels were measured over a 24-hour period. Then each subject received, in random order, single dos...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical research 1995-06, Vol.12 (6), p.844-850
Main Authors: LE COTONNEC, J.-Y, PORCHET, H. C, BELTRAMI, V, KHAN, A, TOON, S, ROWLAND, M
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Biological Assay
Biological Availability
Female
Follicle Stimulating Hormone - pharmacokinetics
Follicle Stimulating Hormone - urine
Hormones. Endocrine system
Humans
Immunohistochemistry
Medical sciences
Pharmacology. Drug treatments
Time Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study determined the pharmacokinetics of urinary human follicle stimulating hormone (u-hFSH) in 12 down-regulated healthy female volunteers. Following pituitary desensitization, baseline FSH serum levels were measured over a 24-hour period. Then each subject received, in random order, single doses of u-hFSH (Metrodin), 75 IU, 150 IU and 300 IU iv, and 150 IU im on four occasions separated by washout periods of one week. Blood and urine samples were collected at preset times. FSH levels were measured by a immuno-radiometric assay and an in vitro rat granulosa cells aromatase bioassay. All doses of u-hFSH were well tolerated. After an iv bolus, the pharmacokinetics of FSH were well described by a two-compartment open model. Immunoassay data showed that the total exposure to FSH was proportional to the administered dose. Mean total clearance of FSH was approximately 0.5 L.h-1 and renal clearance was 0.14 L.h-1. The volume of distribution at steady-state was around 8 liters. The distribution half-life was 2 h and the terminal half-life nearly one day. After im injection, almost two thirds of the administered dose was available systemically. The in vitro bioassay confirmed this pharmacokinetic analysis. The estimation of the elimination half-life of around one day indicates that the maximal effect of a given dose of u-hFSH administered daily cannot be observed until 3 to 4 days of repeated administration. This indicates that, on a pure pharmacokinetic basis, physicians should wait at least 4 days to assess the efficacy of a given dose of u-hFSH and that they should not modify dosage too frequently.
ISSN:0724-8741
1573-904X
DOI:10.1023/A:1016204919251